Trial Profile
A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Male breast cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 30 Mar 2021 Study design changed to sequential.
- 05 Feb 2020 Status changed from recruiting to completed.
- 05 Sep 2019 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.